ArticleFrontiers in medicine2025
Fibrinogen supplementation enhances antivenom efficacy in treating coagulopathy due to hemotoxic snakebite envenoming by
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Timely administration of antivenom remains the cornerstone of treatment for hemotoxic snakebite envenoming, primarily aimed at neutralizing circulating toxins and halting the progression of venom-induced consumption coagulopathy (VICC), thus facilitating gradual recovery of the hemostatic system. However, immediate access to antivenom is not always possible, and variations in venom composition among snake species, along with individual patient differences, can result in significant morbidity (including persistent complications of coagulopathy) and mortality. Methods: This retrospective study evaluated 116 cases of hemotoxic snakebite envenoming caused by Results: In the antivenom-only group, significant reductions were observed in prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), and D-dimer (DD2) levels (all Conclusions: These findings suggest that adjunctive Fg supplementation may improve the laboratory parameters of coagulopathy and reduce the length of hospital stay in hemotoxic snakebite envenoming. However, further clinical evaluations are needed to support the use of Fg as an adjuvant in the management of hemotoxic snakebite envenoming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.